These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

654 related items for PubMed ID: 21613799

  • 1. Decreased RECK and Increased EMMPRIN expression in urothelial carcinoma of the bladder are associated with tumor aggressiveness.
    Wittschieber D, Stenzinger A, Klauschen F, Stephan C, Jung K, Erbersdobler A, Rabien A.
    Pathobiology; 2011; 78(3):123-31. PubMed ID: 21613799
    [Abstract] [Full Text] [Related]

  • 2. Expression and clinical significance of CD147 in genitourinary carcinomas.
    Han ZD, He HC, Bi XC, Qin WJ, Dai QS, Zou J, Ye YK, Liang YX, Zeng GH, Zhu G, Chen ZN, Zhong WD.
    J Surg Res; 2010 May 15; 160(2):260-7. PubMed ID: 19286191
    [Abstract] [Full Text] [Related]

  • 3. Decreased DOC-2/DAB2 expression in urothelial carcinoma of the bladder.
    Karam JA, Shariat SF, Huang HY, Pong RC, Ashfaq R, Shapiro E, Lotan Y, Sagalowsky AI, Wu XR, Hsieh JT.
    Clin Cancer Res; 2007 Aug 01; 13(15 Pt 1):4400-6. PubMed ID: 17671122
    [Abstract] [Full Text] [Related]

  • 4. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.
    Karam JA, Lotan Y, Ashfaq R, Sagalowsky AI, Shariat SF.
    Urology; 2007 Sep 01; 70(3):482-6. PubMed ID: 17905101
    [Abstract] [Full Text] [Related]

  • 5. An immunohistochemical and prognostic evaluation of cathepsin D expression in 105 bladder carcinomas.
    Dickinson AJ, Fox SB, Newcomb PV, Persad RA, Sibley GN, Harris AL.
    J Urol; 1995 Jul 01; 154(1):237-41. PubMed ID: 7776437
    [Abstract] [Full Text] [Related]

  • 6. [Expression and significance of macrophage migration inhibitory factor in bladder urothelial cell carcinoma].
    Guo YS, Dai YP, Li W, Liu LD.
    Zhonghua Zhong Liu Za Zhi; 2011 Jan 01; 33(1):28-31. PubMed ID: 21575460
    [Abstract] [Full Text] [Related]

  • 7. Expression of Maspin in non-muscle invasive bladder carcinoma: correlation with tumor angiogenesis and prognosis.
    Friedrich MG, Toma MI, Petri S, Cheng JC, Hammerer P, Erbersdobler A, Huland H.
    Eur Urol; 2004 Jun 01; 45(6):737-43. PubMed ID: 15149745
    [Abstract] [Full Text] [Related]

  • 8. CD147 overexpression allows an accurate discrimination of bladder cancer patients' prognosis.
    Afonso J, Longatto-Filho A, Baltazar F, Sousa N, Costa FE, Morais A, Amaro T, Lopes C, Santos LL.
    Eur J Surg Oncol; 2011 Sep 01; 37(9):811-7. PubMed ID: 21733655
    [Abstract] [Full Text] [Related]

  • 9. Expression of matrix metalloproteinases in human transitional cell carcinoma of the urinary bladder.
    Sumi T, Yoshida H, Hyun Y, Yasui T, Matsumoto Y, Hattori K, Sugimura K, Kawashima H, Nakatani T, Ishiko O.
    Oncol Rep; 2003 Sep 01; 10(2):345-9. PubMed ID: 12579270
    [Abstract] [Full Text] [Related]

  • 10. RECK expression in pancreatic cancer: its correlation with lower invasiveness and better prognosis.
    Masui T, Doi R, Koshiba T, Fujimoto K, Tsuji S, Nakajima S, Koizumi M, Toyoda E, Tulachan S, Ito D, Kami K, Mori T, Wada M, Noda M, Imamura M.
    Clin Cancer Res; 2003 May 01; 9(5):1779-84. PubMed ID: 12738734
    [Abstract] [Full Text] [Related]

  • 11. Increasing expression of extracellular matrix metalloprotease inducer in renal cell carcinoma: tissue microarray analysis of immunostaining score with clinicopathological parameters.
    Jin JS, Hsieh DS, Lin YF, Wang JY, Sheu LF, Lee WH.
    Int J Urol; 2006 May 01; 13(5):573-80. PubMed ID: 16771728
    [Abstract] [Full Text] [Related]

  • 12. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder.
    Slaton JW, Karashima T, Perrotte P, Inoue K, Kim SJ, Izawa J, Kedar D, McConkey DJ, Millikan R, Sweeney P, Yoshikawa C, Shuin T, Dinney CP.
    Clin Cancer Res; 2001 Sep 01; 7(9):2840-53. PubMed ID: 11555602
    [Abstract] [Full Text] [Related]

  • 13. Invasive micropapillary urothelial carcinoma of the bladder.
    Lopez-Beltran A, Montironi R, Blanca A, Cheng L.
    Hum Pathol; 2010 Aug 01; 41(8):1159-64. PubMed ID: 20381120
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Association of TSC1/hamartin, 14-3-3sigma, and p27 expression with tumor outcomes in patients with pTa/pT1 urothelial bladder carcinoma.
    Mhawech-Fauceglia P, Alvarez V, Fischer G, Beck A, Herrmann FR.
    Am J Clin Pathol; 2008 Jun 01; 129(6):918-23. PubMed ID: 18480009
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Role of matrix metalloproteinase-9 in the basement membrane destruction of superficial urothelial carcinomas.
    Ozdemir E, Kakehi Y, Okuno H, Yoshida O.
    J Urol; 1999 Apr 01; 161(4):1359-63. PubMed ID: 10081908
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer.
    Shariat SF, Tokunaga H, Zhou J, Kim J, Ayala GE, Benedict WF, Lerner SP.
    J Clin Oncol; 2004 Mar 15; 22(6):1014-24. PubMed ID: 14981102
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.